Full history for every metric is available with a Kvantra account

Stock profile
Scholar Rock Holding Corporation logo

Scholar Rock Holding Corporation (SRRK)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
5.87B
Currency USD
KvantraRankAbout38
IValue43
IIQuality15
IIIMomentum61
Current price
48.13 USD-4.45%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m15.418.833.20.00.00.00.6-
Operating profit$m-385-409
Net profit$m-86-132-135-166-246-378-414-379
EPS reported$-3.29-3.22
Operating cashflow per share$-2.62-2.33
Capex per share$0.010.00
FCF per share$-2.62-2.34
Free cash flow$m-301-309
Net debt$m-259-211
Book value equity$m245169
Book value per share$2.141.27
Number of sharesm114.7132.37
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx20.5834.81
P/S LTMx0.0010,301.85
P/FCF LTMx-16.81-18.99
EV/EBITDA LTMx-13.10-14.21
EV/Sales LTMx0.009,932.36
Earnings Yield LTM%-7.48%-6.49%
FCF Yield%-5.95%-5.27%
Quality
ROE%-153.95%-175.27%
ROIC%-108.53%-110.01%
Operating margin%0.00%-71732.3%
Gross margin%0.00%-8236.0%
FCF/Sales%--54254.0%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%--
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-2.76-1.52
Net Debt/EBITDAx0.580.41
EBIT/Net interestx-55.80-29.23
Net debt/market cap%-5.12%-3.59%
Net debt/Equityx-1.05-1.25
Gross debt/equityx0.441.20

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price48.13 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Scholar Rock Holding Corporation (SRRK)

SRRK · NASDAQ · Healthcare
48.13 USD-4.45%
Sign up to track this stock
Benchmarks
KvantraRank38
Market cap5.87B
P/E NTMN/A
P/E TTMN/A
KvantraRank?38 / 100
Value
43
Quality
15
Momentum
61
Financialsin USD
20242025TTM2026E
Analyst target
Consensus
Current48.13 USD
Upside
Price consensus
Last year average price target
Current price48.13 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free